Condition category
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status

Plain English Summary

Background and study aims
Ovarian cancer is the main cause of death from gynaecological malignancies in the UK. Despite massive funding in developing drugs and new treatment strategies, survival rates remain much poorer when compared to other cancers with 3 in 10 women alive at 10 years. In addition, 1 in 10 of all ovarian cancer is familial and most commonly caused by a fault/alteration in the BRCA1 or BRCA2 gene. BRCA1/BRCA2 carriers have a 17-44% risk over their life of developing ovarian cancer and 65-72% risk of developing breast cancer. This is much higher than for women who do not carry the gene who have a 1 in 50 (2%) and a 1 in 8 (12%) lifetime risk of developing ovarian and breast cancer respectively. Focusing on developing strategies to prevent ovarian cancer in women at increased risk may have a significant impact on disease burden. There is currently no screening programme for ovarian cancer available on the NHS unlike other female cancers such as cervical and breast cancer. The current practice is to offer women who are at increased risk, once they have completed their family, surgery to remove their fallopian tubes and ovaries. This procedure is called risk reducing salpingo-oophorectomy (RRSO). This significantly reduces the risk of ovarian cancer by 90% but leads to early menopause. This has serious implications on a woman's general health. Not only does early menopause result in menopausal type symptoms such as hot flushes, changes in mood and pain during intercourse, it also increases the risk of osteoporosis (brittle bones), heart disease, stroke and dementia. Current research suggests that many cancers of the ovary actually start in the fallopian tube. This has led to the proposal of an alternative strategy which involves offering women surgery in two stages. The first operation involves removing the fallopian tubes. The second operation involves removing the ovaries after the patient has gone through the menopause (average age 51 in the UK). The advantage of this new surgical prevention strategy is that it offers some protection against ovarian cancer in young women whilst avoiding the negative health consequences of early menopause which can have a significant impact on quality of life. At present the precise level of benefit obtained from removing the tubes alone is not known. There are no research studies to show whether this two-stage procedure is acceptable and effective for preventing ovarian cancer. Further research is needed to establish this. The aim of this study is to collect the views of women at increased risk on this ‘two-stage’ strategy to prevent ovarian cancer.

Who can participate?
Women aged over 18, living in the UK who are at increased risk of developing tubal/ovarian cancer because they carry an alteration/fault in the BRCA1/BRCA2 gene or have a strong family history of breast and ovarian cancer or ovarian cancer alone.

What does the study involve?
Participants complete an online or paper questionnaire to gather information about their attitudes towards the two-staged surgical approach to reduce the risk of ovarian cancer. The questionnaire is conducted just once per participant. There are no follow up questionnaires.

What are the possible benefits and risks of participating?
Participants will help researchers understand how women feel about this new two-staged surgical approach of preventing ovarian cancer. It will help develop future research studies for ovarian cancer prevention and benefit the health of women at increased risk of ovarian cancer in the future. The drawback to participating is the inconvenience of completing a questionnaire.

Where is the study run from?
Queen Mary University of London (UK)

When is the study starting and how long is it expected to run for?
October 2017 to March 2020

Who is the main contact?
1. Dr Ranjit Manchanda (scientific)
2. Dr Faiza Gaba (public)

Trial website

Contact information



Primary contact

Dr Ranjit Manchanda


Contact details

Barts Cancer Institute
Room 4
Old Anatomy Building
Queen Mary University of London
Charterhouse Square
United Kingdom
+44 (0)7979884575



Additional contact

Dr Faiza Gaba


Contact details

Barts Cancer Institute
Queen Mary University of London
Charterhouse Square
United Kingdom
+44 (0)2078828491

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

Survey to determine attitudes of women at high risk of ovarian cancer towards Risk Reducing Early Salpingetcomy and Delayed Oophorectomy (RRESDO) for ovarian cancer prevention


Study hypothesis

Risk reducing early salpingectomy with delayed oophorectomy is an acceptable surgical prevention strategy for women who are at increased risk of ovarian cancer.

Ethics approval

West Midlands - Edgbaston Research Ethics Committee, 21/08/2017, REC ref: 17/WM/0324

Study design

Prospective cohort survey study

Primary study design


Secondary study design

Cohort study

Trial setting


Trial type


Patient information sheet

Not available in web format, please use the contact details to request a patient information sheet


Prevention of ovarian cancer


Participants who have met the study's inclusion/exclusion criteria and who have provided informed consent will be given a questionnaire to complete. This will gather information about their attitudes towards a novel two staged surgical approach (risk reducing early salpingectomy with delayed oophorectomy) to reduce the risk of ovarian cancer. The questionnaire may be completed online or using a paper version. The questionnaire is conducted just once per participant. There are no follow up questionnaires.

Intervention type



Drug names

Primary outcome measures

Awareness and interest in an early salpingectomy and delayed oophorectomy strategy for ovarian cancer prevention, measured using a questionnaire at a single timepoint

Secondary outcome measures

There are no secondary outcome measures

Overall trial start date


Overall trial end date


Reason abandoned


Participant inclusion criteria

1. Women ≥18 years
2. At increased risk of developing ovarian cancer due to BRCA1/BRCA2 mutation or on the basis of family history
3. Resident in the UK
4. Able to provide written informed consent

Participant type


Age group




Target number of participants

Up to 1000

Participant exclusion criteria

1. Prior or current diagnosis of tubal/ ovarian/primary peritoneal cancer
2. Inability to read or write

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

Barts Health NHS Trust
St Bartholomew's Hospital West Smithfield
United Kingdom

Trial participating centre

University College Hospital
235 Euston Road Fitzrovia
United Kingdom

Sponsor information


Queen Mary University of London

Sponsor details

Joint Research Management Office
5 Walden Street
E1 2EF
United Kingdom
+44 (0)20 7882 7260

Sponsor type




Funder type


Funder name

Investigator initiated and funded

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Additional documents e.g. protocol are not published. They will not be made available unless specific requests for additional information are made to the chief investigator Ranjit Manchanda in writing. Results of the research will be presented at scientific conferences and published in scientific journals. They will also be made available through cancer charities, patient support groups and the Queen Mary University of London website.

IPD sharing statement
The data sharing plans for the current study are unknown and will be made available at a later date.

Intention to publish date


Participant level data

To be made available at a later date

Results - basic reporting

Publication summary

Publication citations

Additional files

Editorial Notes